Related Experiment Video

Updated: Jul 19, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Recent developments in colorectal cancer treatment by monoclonal antibodies

Dominique Arsene1, Marie-Pierre Galais, Karine Bouhier-Leporrier

  • 1Centre Hospitalier Universitaire de Caen, Service d'Hépato-Gastro-Entérologie et Nutrition, Avenue Côte de Nacre, 14033 Caen Cedex, France. arsene-d@chu-caen.fr

Expert Opinion on Biological Therapy
|October 20, 2006
PubMed

Insights

Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways show significant clinical activity in advanced colorectal cancer, particularly when used with chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Advances in understanding cancer molecular mechanisms and drug discovery technologies enable targeted therapies.
  • Monoclonal antibodies represent a significant class of biological therapies now in clinical use.
  • Targeting key tumorigenesis pathways like EGFR and VEGF has shown promise in colorectal cancer.

Purpose of the Study:

  • To review the clinical status of monoclonal antibodies targeting EGFR and VEGF in colorectal cancer treatment.
  • To discuss the efficacy of anti-EGFR antibodies, such as cetuximab, and anti-VEGF antibodies, such as bevacizumab.
  • To highlight the role of these biological therapies in advanced colorectal cancer management.

Main Methods:

  • Review of clinical data and literature on monoclonal antibody therapies in colorectal cancer.
  • Focus on antibodies targeting epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways.
  • Analysis of treatment outcomes, especially in combination with chemotherapy.

Main Results:

  • Monoclonal antibodies targeting EGFR and VEGF pathways demonstrate significant clinical activity in advanced colorectal cancer.
  • These antibodies are particularly effective when administered in combination with chemotherapy.
  • Cetuximab (anti-EGFR) and bevacizumab (anti-VEGF) are key examples of successful biological therapies.

Conclusions:

  • Monoclonal antibodies targeting EGFR and VEGF are valuable tools in the treatment of advanced colorectal cancer.
  • Combination therapy with chemotherapy enhances the clinical efficacy of these biological agents.
  • The development of targeted monoclonal antibodies marks a significant advancement in cancer therapy.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...